CDC recommends RSV vaccine for older adults who would benefit
As proposed by its Advisory Committee on Immunization Practices, the Centers for Disease Control and Prevention today recommended a single dose of the GSK or Pfizer Respiratory Syncytial Virus vaccine for people aged 60 and older who decide with their health care provider that the vaccine would benefit them. The Food and Drug Administration last month approved the vaccines for use in individuals 60 and older. The first U.S.-licensed vaccines to protect against RSV, they are expected to be available this fall.
Related News Articles
Headline
The AHA's Advancing Health podcast recently celebrated the end of 2024 by releasing highlights from some of its most popular episodes of the year. The roundup…
Perspective
The arrival of the holiday season and the coming New Year remind us of the swift passage of time. But they also demonstrate the timelessness of human kindness.…
Headline
Christine McGuire Chloros, program manager for ChristianaCare's Care for the Caregiver initiative, discusses how the health system has grown its health care…
Chairperson's File
In October 1863, in the middle of the Civil War, President Abraham Lincoln decreed that Thanksgiving be held across the U.S. to “heal the wounds of the nation…
Headline
The Centers for Disease Control and Prevention Sept. 4 published a study in JAMA which found older adults who receive a respiratory syncytial virus vaccine are…
Headline
The Centers for Disease Control and Prevention May 29 published a blog co-authored by AHA, the National Institute for Occupational Safety and Health and the…